Icatibant Accord

Icatibant, the active ingredient in Icatibant Accord, is a bradykinin B2 receptor antagonist presented as an injection solution for subcutaneous use. It is indicated for the treatment of acute hereditary angioedema attacks in patients with confirmed HAE.

GNH USA supplies Icatibant Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product conforms to EU regulatory standards, is manufactured under GMP conditions, and our distribution network ensures timely delivery with appropriate cold‑chain handling where required.

Icatibant is used to manage hereditary angioedema, a bradykinin‑mediated disorder that causes sudden swelling. - Hereditary angioedema type I attacks: provides rapid reduction of swelling and associated pain, improving airway safety. - Hereditary angioedema type II attacks: accelerates resolution of edema episodes, decreasing duration of symptoms. - Bradykinin‑mediated angioedema attacks: alleviates swelling when caused by excess bradykinin, offering prompt symptom control. - Acute HAE episodes in adults: enables self‑administration for timely treatment of attacks.

Icatibant may cause a range of adverse reactions, most of which are related to the injection site or systemic exposure.

Common Side Effects: - Injection site pain: mild to moderate discomfort. - Redness or erythema: localized skin reddening. - Headache: transient headache after dosing.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response. - Airway angioedema: swelling that may compromise breathing. - Severe hypotension: sudden drop in blood pressure.

Before using Icatibant Accord, several safety considerations should be observed. - Confirm diagnosis: ensure patient has hereditary angioedema before administration. - Monitor for hypersensitivity: observe for signs of allergic reaction after injection. - Avoid in known hypersensitivity: do not use in patients with previous icatibant allergy. - Use with caution in pregnancy or lactation: limited safety data, weigh benefits and risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant may interact with other medicines; awareness of major and moderate interactions helps manage risk.

Major Interactions (Avoid): - ACE inhibitors: increase bradykinin levels, raising risk of angioedema. - Angiotensin receptor blockers: may potentiate bradykinin‑mediated effects. - C1‑esterase inhibitor concentrates: concurrent use may be unnecessary and increase adverse event risk.

Moderate Interactions (Monitor Closely): - Estrogen‑containing contraceptives: can affect frequency of HAE attacks. - Other bradykinin B2 antagonists: combined effect may enhance pharmacologic activity.